Spinocerebellar Ataxia Type 17 (SCA17)

Spinocerebellar Ataxia Type 17 (SCA17)

Introduction

Spinocerebellar Ataxia Type 17 (Sca17) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Spinocerebellar Ataxia Type 17 (SCA17), also designated ATX-TBP by current Movement Disorder Society nomenclature, is a rare autosomal dominant neurodegenerative disorder caused by an expanded CAG/CAA trinucleotide repeat in exon 3 of the TBP gene, which encodes the TA-binding protein (TBP). TBP is a general transcription factor essential for RNA polymerase II-mediated transcription and a core component of the TFIID complex. The CAG and CAA codons both encode glutamine, so the expansion produces an abnormally long polyglutamine (polyQ) tract in the TBP protein.[@uncommon] [@isolated]

SCA17 is classified as one of nine known polyglutamine diseases, alongside [Huntington's disease](/mechanisms/huntington-pathway), [DRPLA](/diseases/dentatorubral-pallidoluysian-atrophy), SBMA, and SCA1/SCA2/SCA3/[SCA6](/genes/sca6)/[SCA7](/genes/sca7). The disease was first [@tbp]
identified in 1999 by Koide et al., who described a sporadic case of a 14-year-old female with ataxia and intellectual deterioration harboring a de novo expansion of 63 CAG/CAA [@molecular]
repeats.[@uncommon] [@dilemma]
Subsequently, Nakamura et al. (2001) identified SCA17 in four Japanese pedigrees with 47–55 repeats.[@isolated] [^6]

Spinocerebellar Ataxia Type 17 (SCA17)

Introduction

Spinocerebellar Ataxia Type 17 (Sca17) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Spinocerebellar Ataxia Type 17 (SCA17), also designated ATX-TBP by current Movement Disorder Society nomenclature, is a rare autosomal dominant neurodegenerative disorder caused by an expanded CAG/CAA trinucleotide repeat in exon 3 of the TBP gene, which encodes the TA-binding protein (TBP). TBP is a general transcription factor essential for RNA polymerase II-mediated transcription and a core component of the TFIID complex. The CAG and CAA codons both encode glutamine, so the expansion produces an abnormally long polyglutamine (polyQ) tract in the TBP protein.[@uncommon] [@isolated]

SCA17 is classified as one of nine known polyglutamine diseases, alongside [Huntington's disease](/mechanisms/huntington-pathway), [DRPLA](/diseases/dentatorubral-pallidoluysian-atrophy), SBMA, and SCA1/SCA2/SCA3/[SCA6](/genes/sca6)/[SCA7](/genes/sca7). The disease was first [@tbp]
identified in 1999 by Koide et al., who described a sporadic case of a 14-year-old female with ataxia and intellectual deterioration harboring a de novo expansion of 63 CAG/CAA [@molecular]
repeats.[@uncommon] [@dilemma]
Subsequently, Nakamura et al. (2001) identified SCA17 in four Japanese pedigrees with 47–55 repeats.[@isolated] [^6]

Due to its phenotypic overlap with Huntington's Disease — featuring dementia, psychiatric symptoms, chorea, and parkinsonism — SCA17 is also known as Huntington's Disease-Like 4 (HDL4). [^7]

Epidemiology

SCA17 is among the rarest spinocerebellar ataxias. Key epidemiological data:[^14] [^8]

• Fewer than 100 families with SCA17 have been reported worldwide
• SCA17 accounts for approximately 0.3% of autosomal dominant SCAs globally
• Estimated prevalence in Japan: approximately 0.47 per 1,000,000
• Minimum prevalence in northeast England: 0.16 per 100,000[^14]
• Most reported cases come from Japan, China, Korea, Italy, and England
• Prevalence may be underestimated because some individuals present with a phenotype resembling [Huntington's disease](/mechanisms/huntington-pathway) and may not be tested for TBP expansions

Pathophysiology

TBP Protein Function

TBP is a general transcription factor that binds the TA box in gene promoters and is required for transcription initiation by all three eukaryotic RNA polymerases. It serves as a core component of the TFIID complex. Polyglutamine expansion disrupts these critical transcriptional functions through several mechanisms.[^12] [^9]

Mechanisms of Neurodegeneration

Transcriptional Dysregulation: Expanded polyQ reduces TBP binding to DNA and alters its interactions with other transcription factors. Mutant TBP binds more tightly to TFIIB, altering basal transcription. Mutant TBP also sequesters Sp1, reducing Sp1 occupancy at the TrkA promoter and downregulating TrkA (the high-affinity nerve growth factor receptor) before [Purkinje cell](/cell-types/purkinje-cells) degeneration occurs.[^6] [^10]

Chaperone System Impairment: Mutant TBP binds excessively to the transcription factor NF-Y, impairing NF-Y-mediated expression of chaperones including Hsp70, Hsp25, and HspA5. Age-dependent decline in chaperone activity leads to decreased MANF (mesencephalic astrocyte-derived neurotrophic factor) expression and Purkinje cell degeneration. [^11]

INPP5A Downregulation: In SCA17 knock-in mice, mutant TBP inhibits SP1-mediated transcription of INPP5A, a cerebellum-enriched inositol phosphatase. Loss of INPP5A elevates IP3 levels and contributes to selective Purkinje cell vulnerability. INPP5A overexpression ameliorates degeneration.[^9] [^12]

ER Stress: Misfolded mutant TBP induces [endoplasmic reticulum stress](/mechanisms/endoplasmic-reticulum-stress) in [neurons](/entities/neurons), contributing to cell death.[^8] [^13]

Neuropathological Findings

• Neuronal loss most prominent in the [cerebellum](/brain-regions/cerebellum) (especially [Purkinje cells](/cell-types/purkinje-cells), [striatum](/brain-regions/striatum) ([caudate nucleus](/brain-regions/caudate-nucleus) and [putamen](/brain-regions/putamen), and [cerebral [cortex](/brain-regions/cortex)
• Diffuse nuclear labeling with anti-polyglutamine antibodies is the predominant finding; discrete intranuclear inclusions are less common
• Brain weight is typically reduced, with marked cerebellar and cortical atrophy[^12]

Genetics

Gene and Locus

• Gene: TBP (TA-binding protein)
• Chromosomal location: 6q27
• OMIM: #607136

Repeat Length Classifications

| Category | Repeat Length | Clinical Significance | [^14]
|----------|-------------|----------------------| [^15]
| Normal | 25–40 repeats | No disease |
| Intermediate/Mutable normal | 41–42 repeats | Typically unaffected; may expand in offspring |
| Reduced penetrance | 43–48 repeats | Incomplete penetrance; may require digenic inheritance with STUB1 |
| Full penetrance | 49+ repeats | Fully penetrant for SCA17 |
| Maximum reported | 63 repeats | Koide et al. original case |

Unique Repeat Structure

The SCA17 repeat is unique among polyglutamine diseases because it contains a mixed CAG/CAA repeat with CAA interruptions. This mixed structure contributes to greater meiotic stability compared to pure CAG repeats in other polyQ diseases. Pure CAG repeats show both expansion and contraction, while CAA-interrupted repeats show mostly contraction at lower frequency.[^7]

Anticipation

Anticipation (earlier onset in successive generations) is infrequently documented in SCA17 families due to the stabilizing effect of CAA interruptions. However, families with pure, uninterrupted CAG repeats show instability, anticipation, and paternal expansion bias.[^7]

Digenic Inheritance with STUB1

A landmark discovery by Magri et al. (2022) demonstrated that TBP alleles with 41–46 repeats show digenic inheritance with STUB1 variants. Disease manifests only when both a TBP intermediate expansion AND a heterozygous pathogenic STUB1 variant are present. TBP alleles with 47 or more repeats cause monogenic dominant SCA17 independently of STUB1.[^10]

De Novo Expansions

The original Koide et al. case was a de novo expansion (63 repeats arising from a paternal allele in a sporadic case), demonstrating that SCA17 can occur without family history.[@uncommon]

Clinical Features

SCA17 presents with marked clinical heterogeneity. Age of onset ranges from 3 to 55 years.[@molecular], [^11]

Core Features

• Cerebellar ataxia: Gait and limb ataxia, dysarthria, dysphagia — present in most patients though may not be the presenting symptom
• Dementia/cognitive decline: A distinguishing feature of SCA17 compared to most other SCAs; may be the presenting symptom and can precede ataxia; ranges from mild executive dysfunction to severe dementia
• Psychiatric symptoms: Depression, psychosis, behavioral disturbances, personality changes; may be the earliest manifestation, leading to misdiagnosis as a primary psychiatric disorder
• Involuntary movements: Chorea (often prominent, leading to the HDL4 designation), [dystonia](/diseases/dystonia), myoclonus
• Parkinsonism: Bradykinesia, rigidity, postural instability
• Pyramidal signs: Spasticity, hyperreflexia, extensor plantar responses
• Seizures/epilepsy: Present in a subset; helps distinguish SCA17 from other SCAs

The Huntington's Disease-Like 4 Phenotype

When psychiatric symptoms, dementia, chorea, and parkinsonism predominate — especially with smaller repeat expansions in the 43–48 range — the presentation closely mimics [Huntington's disease](/mechanisms/huntington-pathway). The current nomenclature ATX-TBP encompasses both the SCA17 and HDL4 presentations.

Diagnosis

Genetic Testing

The definitive diagnosis requires molecular [genetic testing](/diagnostics/genetic-testing) demonstrating an expanded CAG/CAA repeat in the TBP gene. Testing must account for the mixed repeat structure. Repeat-primed PCR and/or fragment analysis followed by sequencing are used.

Neuroimaging

• MRI: Shows cerebellar atrophy (often marked) with milder cerebral cortical atrophy and relative brainstem sparing. Caudate nucleus atrophy is a distinctive finding detectable even in presymptomatic mutation carriers
• FDG-PET: Demonstrates reduced glucose metabolism in the caudate nucleus and putamen in both manifest patients and presymptomatic carriers[^13]

Differential Diagnosis

| Condition | Key Distinguishing Features |
|-----------|---------------------------|
| [Huntington's disease](/mechanisms/huntington-pathway) | [HTT](/proteins/htt-protein) CAG expansion; characteristic caudate atrophy pattern |
| [DRPLA](/diseases/dentatorubral-pallidoluysian-atrophy) | ATN1 expansion; more prominent brainstem involvement, white matter changes |
| SCA1, SCA2, SCA3 | SCA17 has more prominent dementia, psychiatric features, and chorea |
| [frontotemporal dementia](/diseases/frontotemporal-dementia) | May mimic SCA17 when cognitive/behavioral symptoms predominate |

Treatment

There is currently no disease-modifying therapy for SCA17. Management is entirely symptomatic and supportive.[^12]

Symptomatic Management

• Ataxia: Physical therapy, occupational therapy, speech therapy; off-label use of [riluzole](/therapeutics/riluzole) or 4-aminopyridine may provide modest benefit
• Psychiatric symptoms: Antidepressants, antipsychotics, mood stabilizers as appropriate
• Seizures: Standard antiepileptic medications
• Parkinsonism: [Levodopa](/therapeutics/levodopa) (response is typically limited or absent)
• Chorea/dystonia: [Deep brain stimulation](/therapeutics/deep-brain-stimulation) targeting the GPi has shown benefit for dystonia in individual cases
• Rehabilitation: Multidisciplinary care including physical therapy, occupational therapy, speech-language pathology, and cognitive rehabilitation

Current Research

Animal Models

Several SCA17 mouse models have been developed, including TBP-105Q knock-in mice that recapitulate progressive ataxia, Purkinje cell loss, and striatal degeneration. These have been instrumental in identifying the INPP5A and MANF pathways.[^9]

Therapeutic Targets Under Investigation

MANF Pathway: Increasing MANF expression ameliorated SCA17 neuropathology in TBP-105Q knock-in mice. Piperine, a natural alkaloid from black pepper, was identified as a potent MANF inducer that reduces ER stress and alleviates mutant TBP toxicity.[^8]

INPP5A Pathway: Overexpression of INPP5A reduces IP3 levels and rescues Purkinje cell degeneration in SCA17 knock-in mice, identifying IP3 signaling as a therapeutic target.[^9]

Antisense Oligonucleotides (ASOs): While [ASO therapies](/therapeutics/antisense-oligonucleotide-therapy) have advanced furthest for SCA2 and SCA3, the approach is being explored for SCA17. The challenge is that TBP is an essential transcription factor, requiring allele-selective knockdown strategies.

[Gene Therapy](/therapeutics/gene-therapy): AAV-mediated gene replacement, [CRISPR](/therapeutics/crispr-gene-editing)-based genome editing, and RNA interference strategies are in preclinical development across the polyglutamine SCA spectrum.

External Links

• [GeneReviews: Spinocerebellar Ataxia Type 17](https://www.ncbi.nlm.nih.gov/books/NBK1438/)
• [OMIM #607136: Spinocerebellar Ataxia Type 17](https://omim.org/entry/607136)

See Also

• [Purkinje cell](/cell-types/purkinje-cells)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/mechanisms/huntington-pathway)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Astrocytes](/entities/astrocytes)
• [Cerebral Cortex](/brain-regions/cortex)
• [Gene Therapy](/therapeutics/gene-therapy)
• [All Diseases](/diseases)

Background

The study of Spinocerebellar Ataxia Type 17 (Sca17) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [An uncommon cause of chorea, monoballismus and bilateral putaminal rim sign in an elderly man.](https://pubmed.ncbi.nlm.nih.gov/41207981/) (2026 Feb) - Acta neurologica Belgica
• [Isolated Generalized Chorea in a Patient with Small-Expanded Allele Spinocerebellar Ataxia 17.](https://pubmed.ncbi.nlm.nih.gov/40478462/) (2025 Jun 6) - Cerebellum (London, England)
• [TBP Repeat Expansion Analysis in Patients Carrying Heterozygous STUB1 Variants.](https://pubmed.ncbi.nlm.nih.gov/39950762/) (2025 May) - Movement disorders : official journal of the Movement Disorder Society
• [Molecular Mechanisms of Spinocerebellar Ataxia Type 17.](https://pubmed.ncbi.nlm.nih.gov/39614971/) (2025 May) - Molecular neurobiology
• [Dilemma in differentiation of spinocerebellar ataxia type 17 from Huntington's disease: comorbidity or independent disease?](https://pubmed.ncbi.nlm.nih.gov/37855597/) (2024 Dec) - The International journal of neuroscience

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References